Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalOncologyColorectal CancerOther

CircKPNA2 promotes colorectal cancer via RIN1-Ras pathway activation

The upregulation of circKPNA2 in colorectal cancer presents a significant opportunity for new therapeutic strategies. Targeting this pathway could reshape treatment paradigms and enhance patient outcomes in a highly prevalent malignancy.

Published: June 21, 2026
Updated: June 21, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Colorectal Cancer
Indication: colorectal cancer therapies
Trial SummaryCLN

Phase III

colorectal cancer therapies

Status

Active

Signal Score

8.4

Signal assessment

Signal strength

high

Confidence level

high

Signalhigh
Confidencehigh

Strategic implication

The upregulation of circKPNA2 in colorectal cancer presents a significant opportunity for new therapeutic strategies. Targeting this pathway could reshape treatment paradigms and enhance patient outcomes in a highly prevalent malignancy.

Why it matters

The upregulation of circKPNA2 in colorectal cancer presents a significant opportunity for new therapeutic strategies. Targeting this pathway could reshape treatment paradigms and enhance patient outcomes in a highly prevalent malignancy.

What changed

Other

Analysis

CircKPNA2 is upregulated in colorectal cancer and activates the RIN1-Ras pathway, promoting tumor growth.

The upregulation of circKPNA2 in colorectal cancer presents a significant opportunity for new therapeutic strategies. Targeting this pathway could reshape treatment paradigms and enhance patient outcomes in a highly prevalent malignancy.

Monitor developments in circKPNA2-targeted therapies and clinical trials assessing its role in CRC treatment.

Sources & Humanexa intelligence

Source links

  • CircKPNA2 promotes colorectal cancer via RIN1-Ras pathway activation ↗

Related Humanexa pages

  • CircKPNA2 promotes colorectal cancer via RIN1-Ras pathway activation →

Related signals

Trial SummaryCLN

Phase III

Gastroenterology / Ulcerative Colitis

Status

Active

Sponsor

Eli Lilly

Signal Score

8.2

Clinicalhigh signal

Eli Lilly's LY4268989 Study with Mirikizumab in Ulcerative Colitis Underway

A clinical trial is evaluating the safety and effectiveness of LY4268989 co-administered with mirikizumab in adults with moderately to severely active ulcerative colitis.

June 21, 2026Read signal →
Trial SummaryCLN

Phase III

Neurology / Multiple System Atrophy

Status

Active

Sponsor

Teva

Signal Score

8.2

Clinicalhigh signal

Teva's TEV-56286 Trial for Multiple System Atrophy Underway

Teva is conducting a trial to evaluate the efficacy and safety of TEV-56286 in adults with Multiple System Atrophy.

June 21, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.